Intercept Pharmaceuticals, Inc. (ICPT)

Intercept Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2022	2021	2020	2019	2018
Revenue	285.71	260.75	233.97	252	179.8
Revenue Growth (YoY)	9.57%	11.45%	-7.16%	40.15%	37.30%
Cost of Revenue	0.98	1.21	2.35	4.21	2.52
Gross Profit	284.73	259.55	231.62	247.79	177.29
Selling, General & Admin	176.3	177.49	260.5	317.42	255.47
Research & Development	176.64	182.75	189.03	242.8	207.3
Other Operating Expenses	0	-0.28	11.81	0	0
Operating Expenses	352.94	359.95	461.34	560.22	462.78
Operating Income	-68.22	-100.41	-229.73	-312.43	-285.49
Interest Expense / Income	21.39	54.42	48.05	41.14	30.52
Other Expense / Income	-311.42	-63.4	-2.9	-8.89	-6.77
Pretax Income	221.82	-91.43	-274.88	-344.68	-309.24
Net Income	221.82	-91.43	-274.88	-344.68	-309.24
Shares Outstanding (Basic)	34	32	33	32	28
Shares Outstanding (Diluted)	34	32	33	32	28
Shares Change	6.09%	-3.26%	4.16%	11.21%	13.61%
EPS (Basic)	6.56	-2.87	-8.34	-10.89	-10.86
EPS (Diluted)	6.56	-2.87	-8.34	-10.89	-10.86
Free Cash Flow	-27.35	-41.46	-175.76	-237.75	-240.88
Free Cash Flow Per Share	-0.81	-1.30	-5.33	-7.51	-8.46
Gross Margin	99.66%	99.54%	98.99%	98.33%	98.60%
Operating Margin	-23.88%	-38.51%	-98.19%	-123.98%	-158.78%
Profit Margin	77.64%	-35.06%	-117.49%	-136.78%	-171.99%
Free Cash Flow Margin	-9.57%	-15.90%	-75.12%	-94.34%	-133.97%
EBITDA	245.46	-29.48	-218.61	-294.49	-274.14
EBITDA Margin	85.91%	-11.31%	-93.44%	-116.86%	-152.46%
Depreciation & Amortization	2.26	7.53	8.21	9.05	4.58
EBIT	243.2	-37.01	-226.83	-303.54	-278.72
EBIT Margin	85.12%	-14.19%	-96.95%	-120.45%	-155.01%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).